Atrial Fibrillation with RVR — ED Rate vs Rhythm

Key Points

• Cardiovert immediately when AF is causing hemodynamic instability.
• Stable AF management begins with identifying and treating the precipitating illness.
• Beta blockers or diltiazem/verapamil are common first-line rate-control agents when physiology permits.
• Avoid diltiazem and verapamil in significant HFrEF or decompensated systolic heart failure.
• Do not give AV-nodal blockers to preexcited AF with an accessory pathway.
• Anticoagulation decisions depend on stroke risk and AF duration, not simply whether the rhythm was converted.
• Emergency cardioversion should not be delayed for anticoagulation when the patient is unstable.
• New AF during acute illness deserves follow-up because recurrence is common.

Algorithm

1. Confirm AF on ECG and assess blood pressure, perfusion, ischemia, pulmonary edema, and mental status.
2. If instability is caused by AF, perform immediate synchronized cardioversion.
3. If stable, identify triggers and assess ventricular function and preexcitation before selecting a drug.
4. Use beta blocker or nondihydropyridine calcium-channel blocker for rate control when appropriate; consider digoxin or amiodarone in selected physiology.
5. Correct potassium, magnesium, hypoxemia, volume abnormalities, infection, thyroid disease, or other triggers.
6. Determine AF duration and cardioversion anticoagulation requirements before elective rhythm control.
7. Assess long-term stroke-prevention indication and choose anticoagulation when appropriate.
8. Arrange cardiology or primary-care follow-up for recurrence monitoring and rhythm/risk-factor strategy.

Clinical Synopsis & Reasoning

AF produces an irregularly irregular ventricular rhythm without organized atrial activity. Confirm the rhythm on 12-lead ECG rather than assuming every irregular tachycardia is AF. Assess whether AF is the primary cause of instability or a physiologic response to sepsis, hemorrhage, hypoxemia, thyrotoxicosis, pulmonary embolism, pain, alcohol withdrawal, or another acute stressor. Treating the precipitant can be as important as directly slowing the ventricular rate. New-onset AF during acute illness has meaningful recurrence risk and should not automatically be dismissed as transient.

Hemodynamic instability attributable to AF includes shock, ongoing myocardial ischemia, severe hypotension, altered perfusion, or acute heart failure. In that setting, synchronized cardioversion is the fastest effective rhythm-control method. In stable patients, rate control is often appropriate initially. Beta blockers and diltiazem or verapamil are effective when blood pressure and ventricular function allow. Avoid nondihydropyridine calcium-channel blockers in moderate or severe HFrEF because negative inotropy can worsen decompensation. Digoxin has slower onset and may be useful as an adjunct in selected heart-failure or hypotensive patients. IV amiodarone can provide rate and rhythm effects in critically ill patients but carries cardioversion and anticoagulation implications.

Any rhythm-control plan must consider stroke risk. When AF duration is 48 hours or more, unknown, or likely prolonged, elective cardioversion generally requires appropriate preprocedural anticoagulation or a transesophageal echocardiography-guided strategy, followed by post-cardioversion anticoagulation according to guideline recommendations. Emergency cardioversion for instability is not delayed for anticoagulation, but anticoagulation should be initiated as soon as feasible unless contraindicated. Long-term anticoagulation is based on thromboembolic risk, not on whether sinus rhythm was restored.

Treatment Strategy & Disposition

For unstable AF, perform synchronized cardioversion with sedation when feasible without delaying shock delivery. The 2025 AHA adult advanced life support guideline recognizes synchronized cardioversion as the acute treatment for unstable tachyarrhythmias. Use sufficient initial energy according to device waveform and local protocol, and escalate if the first shock fails. Treat hypoxia, shock, electrolyte disturbance, and the underlying trigger concurrently.

For stable RVR, choose a rate-control agent based on ventricular function and physiology. IV metoprolol or esmolol is useful when sympathetic tone is high and blood pressure tolerates beta blockade. IV diltiazem is effective when EF is preserved and acute decompensated HFrEF is not present. Digoxin can be added when blood pressure limits other agents, particularly in HFrEF, but it is less effective in high catecholamine states. Magnesium can be a useful adjunct. Avoid AV-nodal blockers in preexcited AF because blocking the AV node can accelerate conduction through an accessory pathway and provoke ventricular fibrillation; procainamide or cardioversion is preferred in that scenario.

After acute control, determine whether early rhythm control, antiarrhythmic therapy, or catheter ablation is appropriate. The 2023 AF guideline places greater emphasis on early rhythm-control strategies in selected patients and on aggressive management of obesity, sleep apnea, hypertension, alcohol use, and other modifiable factors. Assess anticoagulation using a validated thromboembolic-risk framework and bleeding considerations. Arrange follow-up because AF discovered during hospitalization often recurs.

Epidemiology / Risk Factors

• AF is the most common sustained arrhythmia in adults and prevalence rises markedly with age.
• Hypertension, obesity, sleep apnea, heart failure, valvular disease, diabetes, alcohol, and thyroid disease increase risk.
• AF is common during sepsis, surgery, and other acute hospitalization.
• Stroke risk is heterogeneous and rises with age and vascular comorbidity.
• Lifestyle and risk-factor modification reduce AF burden and improve broader cardiovascular health.

Investigations

Common ED Agents

Pharmacology

Prognosis / Complications

• Most stable episodes can be controlled without immediate invasive therapy.
• Hemodynamic instability, severe HFrEF, or acute coronary disease increases short-term risk.
• AF increases long-term ischemic-stroke risk when thromboembolic risk factors are present.
• Recurrence is common even after apparently transient hospital-associated AF.
• Appropriate anticoagulation and risk-factor treatment substantially improve long-term outcomes.

Patient Education / Counseling

• Explain the difference between rate control, rhythm control, and stroke prevention because each addresses a different risk.
• Take anticoagulants consistently if prescribed and report major bleeding promptly.
• Limit excessive alcohol, address sleep apnea, control blood pressure, and pursue healthy weight and physical activity.
• Check pulse or use approved monitoring tools when symptoms recur, but seek emergency care for syncope, chest pain, severe dyspnea, or persistent rapid heart rate with weakness.
• Do not stop rate-control or anticoagulant medication just because the rhythm feels normal.
• Keep follow-up to reassess rhythm burden, ventricular function, and candidacy for ablation or other rhythm-control therapy.

Notes

The acute goal is not a particular heart-rate number in isolation. Treatment should improve perfusion and symptoms without worsening heart failure or masking the true cause of physiologic stress.

The 2023 AF guideline and AHA statements on acute AF emphasize that AF occurring during hospitalization has meaningful recurrence and requires a long-term plan for rhythm surveillance and stroke prevention.

References

1. 2023 ACC AHA Atrial Fibrillation Guideline — Link
2. AHA 2025 Adult Advanced Life Support — Link